Screener
Halozyme Therapeutics HALO Asset turnover
Asset turnover at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's asset turnover?
- Halozyme Therapeutics (HALO) reported asset turnover of 0.7× in Q2 2026.
- How has Halozyme Therapeutics's asset turnover changed year-over-year?
- Halozyme Therapeutics's asset turnover increased by 22.6% year-over-year, from 0.6× to 0.7×.
- What is the long-term trend for Halozyme Therapeutics's asset turnover?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's asset turnover has grown at a 5.4% compound annual growth rate (CAGR), from 0.5× to 0.6×.
- What does asset turnover mean?
- Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.
Ask your AI about Halozyme Therapeutics's asset turnover.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude